Antiplatelet Drugs
Antiplatelet drugs prevent blood clots by stopping platelets from clumping together. Since platelet-driven clots are the main cause of heart attacks and strokes, these medications are some of the most commonly prescribed cardiovascular drugs you'll encounter in practice. This section covers how they work, the major drugs in this class, and what you need to know as a nurse to administer them safely.
Key Features and Mechanisms of Antiplatelet Drugs
Antiplatelets reduce the risk of arterial thrombosis (heart attack, stroke) by inhibiting platelet activation, adhesion, and aggregation. Unlike anticoagulants, which target clotting factors in the coagulation cascade, antiplatelets target the platelets themselves.
There are three main mechanisms of action:
- Cyclooxygenase (COX) inhibition: Aspirin irreversibly inhibits COX-1, which prevents the production of thromboxane A2, a chemical that normally signals platelets to activate and aggregate. Because the inhibition is irreversible, the effect lasts for the entire lifespan of the platelet (about 7–10 days).
- ADP receptor antagonism: Clopidogrel, prasugrel, and ticagrelor block P2Y12 receptors on platelets. Adenosine diphosphate (ADP) normally binds to these receptors to amplify platelet aggregation, so blocking them significantly reduces clot formation.
- Glycoprotein IIb/IIIa receptor inhibition: Abciximab, eptifibatide, and tirofiban block the GP IIb/IIIa receptor, which is the final common pathway of platelet aggregation. This receptor is what allows fibrinogen to cross-link platelets together, so blocking it is the most direct way to prevent aggregation.
Indications, Actions, and Side Effects of Common Antiplatelet Medications
Each antiplatelet drug has specific indications, and the differences between them matter clinically. The major bleeding risk is shared across the entire class, but individual drugs carry unique considerations.
Aspirin
- Indications: Primary and secondary prevention of cardiovascular events; acute coronary syndrome (ACS)
- Action: Irreversibly inhibits COX-1, blocking thromboxane A2 production
- Side effects: GI bleeding (the most common concern), increased bleeding risk overall, and GI upset. Low-dose aspirin (81 mg) is standard for prevention; higher doses (325 mg) may be used acutely.
Clopidogrel (Plavix)
- Indications: ACS, post-percutaneous coronary intervention (PCI) with stent placement, stroke prevention
- Action: Irreversible P2Y12 receptor antagonist; it's a prodrug, meaning the liver must convert it to its active form via CYP2C19
- Side effects: Bleeding; rarely, thrombotic thrombocytopenic purpura (TTP), a serious condition involving widespread microclot formation. Genetic variations in CYP2C19 can make some patients poor metabolizers, reducing the drug's effectiveness.
Prasugrel (Effient)
- Indications: ACS managed with PCI
- Action: Irreversible P2Y12 receptor antagonist, more potent and with more consistent activation than clopidogrel
- Side effects: Higher bleeding risk than clopidogrel. Contraindicated in patients with a history of stroke or transient ischemic attack (TIA) due to increased risk of intracranial hemorrhage.
Ticagrelor (Brilinta)
- Indications: ACS (with or without PCI)
- Action: Reversible P2Y12 receptor antagonist, which means its effects wear off faster once discontinued (important for surgical planning)
- Side effects: Bleeding and dyspnea (shortness of breath), which occurs in up to 14% of patients. The dyspnea is usually mild and self-limiting but should be assessed. Must be taken twice daily, unlike the once-daily dosing of clopidogrel and prasugrel.
Glycoprotein IIb/IIIa Inhibitors (abciximab, eptifibatide, tirofiban)
- Indications: ACS and PCI, typically used in acute hospital settings
- Action: Block the GP IIb/IIIa receptor, preventing the final step of platelet aggregation
- Side effects: Bleeding and thrombocytopenia (low platelet count). These are given IV only, so you'll see them in acute care, not outpatient settings. Platelet counts should be monitored within hours of starting the infusion.
Critical Nursing Considerations When Administering Antiplatelet Drugs
1. Assessment before administration
- Evaluate bleeding risk: Ask about history of GI bleeds, hemorrhagic stroke, recent surgery, or active bleeding.
- Review the medication list for drugs that increase bleeding risk (other antiplatelets, anticoagulants, NSAIDs, SSRIs).
- Check for relevant allergies, especially aspirin sensitivity.
2. Drug interactions
- Concurrent use of NSAIDs with aspirin can both increase GI bleeding risk and interfere with aspirin's antiplatelet effect.
- Proton pump inhibitors (especially omeprazole) can reduce the effectiveness of clopidogrel by inhibiting CYP2C19. If a PPI is needed, pantoprazole is generally preferred.
- Combining multiple antiplatelets (dual antiplatelet therapy, or DAPT) is common after stent placement but significantly increases bleeding risk.
3. Dosing and administration
- Verify the correct dose for the indication. Aspirin dosing varies widely depending on whether it's being used for prevention (81 mg) versus an acute event (325 mg).
- Ticagrelor requires twice-daily dosing; missing doses reduces its effectiveness more quickly because it's reversible.
- Administer as prescribed regarding food. Aspirin should generally be taken with food to reduce GI irritation.
4. Ongoing monitoring
- Watch for signs of bleeding: unusual bruising, blood in stool or urine, prolonged bleeding from cuts, dark/tarry stools, hematemesis, altered mental status (could indicate intracranial hemorrhage).
- For GP IIb/IIIa inhibitors, monitor platelet counts at baseline, 2–4 hours after initiation, and at 24 hours.
- Assess for therapeutic effectiveness: reduction in recurrent cardiovascular events, absence of stent thrombosis.
5. Patient education (see detailed plan below)
Patient Education Plan for Safe and Effective Use of Antiplatelet Medications
Patient education is one of the most impactful things you can do with these medications. Many adverse events happen because patients don't understand why adherence matters or when to seek help.
Purpose of the medication
- Explain in plain language: "This medication helps keep your blood from forming dangerous clots that could cause a heart attack or stroke." Connect it to their specific diagnosis so it feels relevant.
How to take it correctly
- Take at the same time each day to build a routine.
- Do not skip doses. If a dose is missed, take it as soon as remembered unless it's nearly time for the next dose. Never double up.
- For ticagrelor specifically, reinforce the twice-daily schedule.
Recognizing and reporting side effects
- Teach patients to watch for: unusual or prolonged bleeding, blood in urine or stool, black/tarry stools, excessive bruising, vomiting blood, severe headache with no known cause.
- Instruct them to seek emergency care for signs of serious bleeding or stroke symptoms.
Precautions
- Avoid over-the-counter NSAIDs (ibuprofen, naproxen) unless approved by their provider, as these increase bleeding risk.
- Inform all healthcare providers (including dentists) that they are on antiplatelet therapy before any procedure.
- Never stop the medication without consulting their provider. This is especially critical after stent placement, where abrupt discontinuation can lead to stent thrombosis, a potentially fatal event.
Lifestyle modifications
- Encourage heart-healthy habits that complement the medication: balanced diet, regular physical activity, smoking cessation, and stress management.
- Remind patients to keep follow-up appointments for lab work and cardiovascular monitoring.
Adherence strategies
- Suggest practical tools: pill organizers, phone alarms, linking the dose to a daily habit (like brushing teeth).
- If cost is a barrier, discuss generic options (clopidogrel is available as a generic) or patient assistance programs.